139 related articles for article (PubMed ID: 1296807)
1. Stimulation of host resistance against tumors by glycyrrhizin, an active component of licorice roots.
Suzuki F; Schmitt DA; Utsunomiya T; Pollard RB
In Vivo; 1992; 6(6):589-96. PubMed ID: 1296807
[TBL] [Abstract][Full Text] [Related]
2. Curative intravenous adoptive immunotherapy of Meth A murine sarcoma. A histologic and immunohistochemical assessment.
Reichert CM; Rosenstein M; Von Glatz J; Hsu SM; Rosenberg SA
Lab Invest; 1985 Mar; 52(3):304-13. PubMed ID: 3974201
[TBL] [Abstract][Full Text] [Related]
3. [Antitumor effect of Cepharanthin in the double grafted tumor system].
Ebina T; Ishikawa K; Murata K
Gan To Kagaku Ryoho; 1990 Jun; 17(6):1165-71. PubMed ID: 2350192
[TBL] [Abstract][Full Text] [Related]
4. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
Mulé JJ; Yang J; Shu S; Rosenberg SA
J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
[TBL] [Abstract][Full Text] [Related]
5. Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy.
Shu SY; Chou T; Rosenberg SA
J Immunol; 1987 Jul; 139(1):295-304. PubMed ID: 2953816
[TBL] [Abstract][Full Text] [Related]
6. [Antitumor effect of a novel antitumor compound, NC-190, in the double grafted tumor system].
Ebina T; Shishido K; Murata K
Gan To Kagaku Ryoho; 1990 Jul; 17(7):1345-50. PubMed ID: 2369138
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxic T-cell-mediated antitumor effect of levamisole against murine syngeneic fibrosarcoma.
Gomi K; Morimoto M; Nomoto K
Cancer Res; 1982 Oct; 42(10):4197-202. PubMed ID: 6980702
[TBL] [Abstract][Full Text] [Related]
8. Antitumor mechanisms of Z-100, an immunomodulatory arabinomannan extracted from Mycobacterium tuberculosis: the importance of lymphocytes infiltrated into tumor sites.
Sasaki H; Schmitt D; Hayashi Y; Pollard RB; Suzuki F
Nat Immun; 1993; 12(2):104-12. PubMed ID: 8318815
[TBL] [Abstract][Full Text] [Related]
9. Down-regulation of cytotoxic T lymphocyte development by a minor stimulating locus-induced suppressor cascade that involves Lyt-1+ suppressor T cells, IA- macrophages, and their factors.
Chow KP; Battisto JR
J Immunol; 1988 Feb; 140(4):1005-13. PubMed ID: 2963857
[TBL] [Abstract][Full Text] [Related]
10. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
Papa MZ; Mulé JJ; Rosenberg SA
Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
[TBL] [Abstract][Full Text] [Related]
11. Adoptive immunotherapy of a newly induced sarcoma: immunologic characteristics of effector cells.
Shu S; Rosenberg SA
J Immunol; 1985 Oct; 135(4):2895-903. PubMed ID: 2411817
[TBL] [Abstract][Full Text] [Related]
12. Cell therapy with preimmunized effector cells mismatched for minor histocompatible antigens in the treatment of a murine mammary carcinoma.
Morecki S; Yacovlev E; Gelfand Y; Uzi I; Slavin S
J Immunother; 2001; 24(2):114-21. PubMed ID: 11265768
[TBL] [Abstract][Full Text] [Related]
13. Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts.
Gabrilovich DI; Ciernik IF; Carbone DP
Cell Immunol; 1996 May; 170(1):101-10. PubMed ID: 8665590
[TBL] [Abstract][Full Text] [Related]
14. H-40, an antigen controlled by an Igh-linked gene and recognized by cytotoxic T lymphocytes. II. Recognition of H-40 as a tumor antigen in leukemic animals.
Henderson LA; Ciavarra R; Riblet R; Forman J
J Immunol; 1984 Nov; 133(5):2778-85. PubMed ID: 6434638
[TBL] [Abstract][Full Text] [Related]
15. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.
Proietti E; Greco G; Garrone B; Baccarini S; Mauri C; Venditti M; Carlei D; Belardelli F
J Clin Invest; 1998 Jan; 101(2):429-41. PubMed ID: 9435316
[TBL] [Abstract][Full Text] [Related]
16. [Anticancer effects of OK-432 (2). Anticancer actions of M phi activated by OK-432].
Saito M; Aonuma E; Noda T; Nakadate I; Nanjo M; Ebina T; Ishida N
Gan To Kagaku Ryoho; 1983 May; 10(5):1363-71. PubMed ID: 6870302
[TBL] [Abstract][Full Text] [Related]
17. Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice.
Shiloni E; Lafreniere R; Mulé JJ; Schwarz SL; Rosenberg SA
Cancer Res; 1986 Nov; 46(11):5633-40. PubMed ID: 3489526
[TBL] [Abstract][Full Text] [Related]
18. Influence of surgical removal and effect of levamisole on cytotoxic T-cell-mediated antitumor immunity in mice.
Gomi K; Morimoto M; Nomoto K
Cancer Res; 1983 Nov; 43(11):5120-5. PubMed ID: 6604572
[TBL] [Abstract][Full Text] [Related]
19. Suppression of alloimmune cytotoxic T lymphocyte (CTL) generation by depletion of NK cells and restoration by interferon and/or interleukin 2.
Suzuki R; Suzuki S; Ebina N; Kumagai K
J Immunol; 1985 Apr; 134(4):2139-48. PubMed ID: 2579129
[TBL] [Abstract][Full Text] [Related]
20. Effect of continuous administration of interleukin 2 on active specific chemoimmunotherapy with extracted tumor-specific transplantation antigen and cyclophosphamide.
Naito K; Pellis NR; Kahan BD
Cancer Res; 1988 Jan; 48(1):101-8. PubMed ID: 3257158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
